Diamyd's Antigen-Specific Immunotherapy Shows Promise in LADA Patients
核心洞察
Diamyd Medical (搜索)'s Diamyd® immunotherapy demonstrates disease-modifying potential in adults with Latent Autoimmune Diabetes in Adults (搜索) (LADA (搜索)) in a recent pilot trial.
The GADinLADA trial, featuring three intralymphatic injections of Diamyd®, reported no treatment-related severe adverse events, confirming the therapy's safety profile.
Results indicated preservation of insulin-producing capacity, particularly in HLA DR3-DQ2 positive patients, suggesting a precision medicine approach to LADA (搜索) treatment.
The GADinLADA pilot trial, evaluating Diamyd® antigen-specific immunotherapy in adults with Latent Autoimmune Diabetes in Adults (搜索) (LADA (搜索)), has demonstrated promising disease-modifying potential. Published in Diabetes Obesity and Metabolism, the 12-month results indicate that Diamyd® treatment is safe and effective in preserving insulin production in LADA patients.
Safety and Efficacy
The trial, conducted in Norway and Sweden, involved three intralymphatic injections of Diamyd® in LADA (搜索) patients aged 30-70 years, diagnosed within the last 18 months and not yet on insulin therapy. Key findings include the absence of treatment-related severe adverse events, underscoring Diamyd®'s safety profile. Efficacy assessments, using both glucagon-stimulated and mixed-meal stimulated C-peptide measures, revealed promising preservation of insulin-producing capacity.
Precision Medicine Implications
Notably, glucagon-stimulated C-peptide levels indicated a significant preservation of insulin-producing capacity in HLA DR3-DQ2 positive patients (P<0.05 vs HLA DR3-DQ2 negative patients), aligning with observations from previous Diamyd® trials in Type 1 Diabetes (搜索). This suggests a specific efficacy of Diamyd® in individuals carrying this genetic marker, highlighting the potential for a precision medicine approach. All participants remained insulin-independent for at least 12 months following treatment.
Trial Design and Patient Population
The GADinLADA trial aimed to evaluate the safety of Diamyd® in LADA (搜索) patients displaying strong signs of autoimmunity, defined as high titers of GAD (搜索) autoantibodies. Patients were recruited at the Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital in Trondheim, Norway, as well as at the Center for Diabetes in Stockholm, Sweden. The trial's sponsor was the Norwegian University of Science and Technology, with Diamyd Medical (搜索) contributing study drugs, expertise, and financial support for immunological analyses.
LADA and Current Treatment Landscape
LADA (搜索) affects approximately 10% of patients diagnosed with type 2 diabetes and is characterized by an autoimmune destruction of insulin-producing beta cells, similar to type 1 diabetes (搜索) but progressing more slowly. While categorized as autoimmune diabetes, LADA is often treated according to type 2 diabetes guidelines. Patients are typically not insulin-dependent at diagnosis but require insulin therapy within a few years.
Future Directions
Ulf Hannelius, President & CEO of Diamyd Medical (搜索), stated, "The published data in this prominent journal brings to light the transformative potential of Diamyd® for LADA (搜索) patients, aligning closely with the disease-modifying impact seen in type 1 diabetes (搜索)." The company is evaluating regulatory pathways and potential partnerships to bring Diamyd® to LADA patients while advancing its use for type 1 diabetes in the DIAGNODE-3 phase 3 trial.